1. Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
- Author
-
Michihito Miyagi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Toshiaki Takahashi, Haruyasu Murakami, Hideyuki Harada, Keita Mori, and Mitsuru Takahashi
- Subjects
Bone metastases ,Non-small cell lung cancer (NSCLC) ,Osteosclerosis ,Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients. Methods We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30 days and followed up for more than 3 months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3 months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate. Results The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (p
- Published
- 2022
- Full Text
- View/download PDF